Incidence of chemotherapy-induced nausea and vomiting (CINV) after highly and moderately emetogenic therapy in the era of NK-1 inhibitors - perception versus reality

被引：0
|
作者：
Perez-Altozano, J. [1 ]
Majem, M. [1 ]
Calvo, N. [1 ]
Moreno, E. [1 ]
Feliu, A. [1 ]
Gich, I. [1 ]
Mangues, A. [1 ]
Barnadas, A. [1 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70629-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：184 / 184
页数：1
相关论文
共 50 条
  • [1] Incidence of chemotherapy-induced nausea and vomiting after highly and moderately emetogenic chemotherapy in the era of NK-1 receptor antagonists. Perception versus reality
    Majem, M.
    Moreno, E.
    Perez, J.
    Calvo, N.
    Feliu, A.
    Gich, I.
    Tibau, A.
    Mangues, M. A.
    Barnadas, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC)
    Urban, Laszlo
    Poma, Allen
    Dardeno, Michelle Motta
    Martell, Robert E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic therapy (MEC)
    Hesketh, Paul Joseph
    Schwartzberg, Lee Steven
    Modiano, Manuel R.
    Arora, Sujata
    Poma, Allen
    Schnadig, Ian D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice
    Badarudin, Nurul Suhaida
    Shah, Noraida Mohamed
    Kassim, Kamarun Neasa Begam Mohd
    Ismail, Fuad
    Islahudin, Farida
    Tahir, Nurul Ain Mohd
    Yusak, Suhana
    SUPPORTIVE CARE IN CANCER, 2022, 30 (06) : 5339 - 5349
  • [5] A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice
    Nurul Suhaida Badarudin
    Noraida Mohamed Shah
    Kamarun Neasa Begam Mohd Kassim
    Fuad Ismail
    Farida Islahudin
    Nurul Ain Mohd Tahir
    Suhana Yusak
    Supportive Care in Cancer, 2022, 30 : 5339 - 5349
  • [6] Incidence of chemotherapy-induced nausea and vomiting in Taiwan: Perception versus reality
    Liau, CT
    Chu, NM
    Liu, HE
    Yang, GY
    Deuson, R
    Chen, JS
    Liaw, CC
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 778S - 778S
  • [7] Phase II clinical trial overview of the novel neurokinin-1 (NK-1) antagonist, casopitant, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and highly emetogenic chemotherapy
    Rogers, Miriam
    Pence, Christine
    Russo, Mark
    ONCOLOGY NURSING FORUM, 2008, 35 (03) : 557 - 557
  • [8] Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC)
    Schnadig, Ian D.
    Modiano, Manuel R.
    Poma, Allen
    Hedley, Mary Lynne
    Martell, Robert E.
    Schwartzberg, Lee Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists
    Margarita Majem
    Ma Estela Moreno
    Núria Calvo
    Anna Feliu
    Javier Pérez
    Ma Antonia Mangues
    Agustí Barnadas
    Supportive Care in Cancer, 2011, 19 : 1983 - 1990
  • [10] LIKELIHOOD OF A SUBSEQUENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) EVENT IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY (MEC/HEC)
    Feinberg, B.
    Gilmore, J.
    Haislip, S.
    Jackson, J.
    Jain, G.
    Balu, S.
    Buchner, D.
    VALUE IN HEALTH, 2010, 13 (07) : A251 - A251
12345